Shaping the future of retinal care in India: Anti-VEGF therapy now and beyond [0.03%]
塑造印度眼底病治疗的未来：当前和即将面世的抗VEGF疗法
Aashraya Karpe,Ritesh Narula,Daraius Shroff et al.
Aashraya Karpe et al.
From bench to bed: The evolution of anti-vascular endothelial growth factor therapies [0.03%]
从实验室到病床：抗血管内皮生长因子疗法的发展历程
Alok Sen,Gaurav Kohli,Aditi Agarwal et al.
Alok Sen et al.
Intravitreal faricimab in type I retinopathy of prematurity: Probably the first case? [0.03%]
早产儿I型视网膜病变的玻璃体内注射法瑞西马b角蛋白：首例病例？
Vasumathy Vedantham,Ratnagiri Praveen Krishna,Ratnagiri Smriti et al.
Vasumathy Vedantham et al.
Biosimilar anti-vascular endothelial growth factor agents: Clinical outcomes, safety, and cost-effectiveness in India [0.03%]
印度的生物类似药抗血管内皮生长因子药物：临床结果，安全性和成本效益
Debdulal Chakraborty,Tushar Kanti Sinha,Subhendu Boral et al.
Debdulal Chakraborty et al.
Retinal vascular diseases, including neovascular age-related macular degeneration, diabetic macular edema, retinal vein occlusion, myopic choroidal neovascularization, and retinopathy of prematurity, are a major cause of visual morbidity in...
Retinal vein occlusion-related macular edema: An updated review of current evidence and future directions [0.03%]
视网膜静脉阻塞相关的黄斑水肿：现有证据及未来发展方向的最新综述
Shreyas Temkar,Goutham Rajasekar,Aahan D Shah et al.
Shreyas Temkar et al.
Macular edema is the leading cause of visual impairment in retinal vein occlusion (RVO). Management has evolved significantly with advances in retinal imaging and the recognition of vascular endothelial growth factor (VEGF) as a key pathoge...
Anti-vascular endothelial growth factor therapy in uveitis: Bridging inflammation and vascular pathology [0.03%]
抗血管内皮生长因子治疗葡萄膜炎：炎症与血管病理的桥梁作用
Ankush Kawali,Sai Bhakti Mishra,Padmamalini Mahendradas et al.
Ankush Kawali et al.
Anti-vascular endothelial growth factor (VEGF) therapy has emerged as an important adjunct in the management of uveitis, particularly for complications driven by vascular permeability and ischemia, such as uveitic macular edema, inflammator...
Anti-vascular endothelial growth factor therapy in polypoidal choroidal vasculopathy [0.03%]
抗血管内皮生长因子治疗脉络膜新生血管病中的脉样异常血管病灶
Anantharaman Giridhar,T Lekha,Kiran Chandran
Anantharaman Giridhar
The diagnosis and management of polypoidal choroidal vasculopathy (PCV), a complex chorioretinal disease which constitutes 60% of neovascular age-related macular degeneration cases among Asians, have evolved significantly in the last decade...
Neovascular age-related macular degeneration management - Beyond anti-VEGF [0.03%]
老年黄斑变性治疗的新方法——抗VEGF之外的选择
Apoorva Ayachit,Shailesh Rao,Shadma Eqbal et al.
Apoorva Ayachit et al.
Intravitreal anti-vascular endothelial growth factor (VEGF) therapy has transformed neovascular age-related macular degeneration (nAMD) into a chronic, treatable condition. However, real-world outcomes remain limited by treatment burden, li...
P Mahesh Shanmugam
P Mahesh Shanmugam